Christopher Simon - 15 May 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role: President & CEO, Director
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon
Issuer symbol: HAE
Transactions as of: 15 May 2023
Transactions value $: -$141,487
Form type: 4
Filing time: 17 May 2023, 16:25:16
Previous filing: 16 May 2023
Next filing: 19 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HAE	Common Stock	Award		+18.2K	+8.91%		223K	15 May 2023	Direct	F1, F2, F3
transaction	HAE	Common Stock	Tax liability	-$141K	-1.59K	-0.71%	$89.21	221K	16 May 2023	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HAE	Non-qualified Stock Option (Right to Buy)	Award	$0	+41.2K		$0.00	41.2K	15 May 2023	Common Stock	41.2K	$89.16	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2	Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3	This number includes unvested RSUs previously reported.
F4	Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
F5	Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.